Assessment of proportional hazard rate of endocrine disease in major beta-thalassemia in Shiraz 2005-2006

Author(s):
Hossein AnsariHossein Ansari1,*, HR TabatabaeiHR Tabatabaei2
1Public health Department, School of public Health, Zahedan University of Medical Sciences, Zahedan, Iran
2Epidemiology Dept. Faculty of Health, Shiraz University of Medical Sciences, Shiraz, Iran
*Corresponding Author: Public health Department, School of public Health, Zahedan University of Medical Sciences, Zahedan, Iran Email: [email protected]

Zahedan Journal of Research in Medical Sciences:Vol. 8, issue 3; e94895
Published online:Jul 30, 2006
Article type:Research Article
Received:Mar 11, 2006
Accepted:May 12, 2006
How to Cite:Ansari H, Tabatabaei H. Assessment of proportional hazard rate of endocrine disease in major beta-thalassemia in Shiraz 2005-2006. Zahedan J Res Med Sci. 2006;8(3):e94895. doi:

Abstract

Background: Thalassemia is the most common hemolytic anemia in Iran and around the world
that needs regular blood transfusion. Transfusion leads to iron overload in the body. Absence or
irregular chelation therapy in these patients leads to various complications such as cardiac
diseases, endocrine disorders and infectious diseases like HIV and hepatitis. The purpose of this
study was to evaluate the hazard rate of endocrine disease and related factors using COX model.
Materials and Methods: This cross-sectional study was carried out on eight-hundred and six
thalassemic (406 male and 400 female) patients referring to Cooley’s ward of Dastgheib hospital in
Shiraz who were studied using a structured questionnaire through enumeration method. Age of
occurrence, demographic information, age of onset and type of transfusion, and age of onset and
method of chelation therapy were specified. Specialist physicians diagnosed the complications.
Data were analyzed using descriptive and analytical (Proportional hazard rate and its confidence
interval using COX model) statistical.
Results: The range of the subject’s age was between 1- 43 years and mean age ± SD was
15.34±6.82 years. The prevalence rate of hypogonadism, hypothyroidism, hyperparathyroidism and
diabetes mellitus was 14.5%, 2.4%, 6.9% and 7.5% respectively and the mean age of onset of
hypogonadism, hypothyroidism, hypoparathyroidism and diabetes mellitus was 18.42±3.6,
15.83±3.5, 16.98 ± 4.5 and 17.19 ± 4.8 respectively. There was a significant association between
proportional hazard rate of all complications and age of chelation therapy onset (P<0/05).
Proportional hazard rate of hypogonadism also was related to the sex and educational level of the
patient’s mothers (P<0/05). Proportional hazard rate of hyperparathyroidism also was related to
sex and occupational status of the patient’s mothers.
Conclusions: Early onset of blood transfusion with late onset of chelating increases the
occurrence probability and early onset of complications. To prevent these complications, it is
recommended that onset of blood transfusion be according to the onset of chelating. Educational
level of parents and educating parents and patients is very important. Progression of complications
can be prevented by regular survey and early diagnosis of complications and can lead to high
efficacy of patients.

Fulltext

The full text of this article is available on the PDF file.

References

  • 1.
    The References of this article are available on the PDF file.

Copyright

© 2006, Author(s). This open-access article is available under the Creative Commons Attribution 4.0 (CC BY 4.0) International License (https://creativecommons.org/licenses/by/4.0/), which allows for unrestricted use, distribution, and reproduction in any medium, provided that the original work is properly cited.

Similar Articles

21
Mar
2006

Assessment of survival without cardiac disease of thalassemic patients of Shiraz, Iran, 2005

H Ansari,
hamid reza tabatabaee

Ansari H, tabatabaee HR. Assessment of survival without cardiac disease of thalassemic patients of Shiraz, Iran, 2005. Zahedan J Res Med Sci. 2006;8(1):e94917. doi:

30
Apr
2008

Evaluation of Endocrine Disorders in Patients with Thalassemia Major

F Najafipour

Najafipour F. Evaluation of Endocrine Disorders in Patients with Thalassemia Major. Int J Endocrinol Metab. 2008;6(2):. doi:

10
Feb
2018
Hypothyroidism and Hypoparathyroidism in Thalassemia Major Patients: A Study in Sistan and Baluchestan Province, Iran

Hypothyroidism and Hypoparathyroidism in Thalassemia Major Patients: A Study in Sistan and Baluchestan Province, Iran

Ali Bazi,
Hadi Harati,
Ali Khosravi-Bonjar,
Elham Rakhshani,
Mojtaba Delaramnasab

Bazi A, Harati H, Khosravi-Bonjar A, Rakhshani E, Delaramnasab M. Hypothyroidism and Hypoparathyroidism in Thalassemia Major Patients: A Study in Sistan and Baluchestan Province, Iran. Int J Endocrinol Metab. 2018;16(2):e13228. doi: https://doi.org/10.5812/ijem.13228

8
Jan
2013

Prevalence of Diabetes and Impaired Glucose Tolerance Test in Patients with Thalassemia Major

Mehdi Jahantigh,
Majid Naderi,
Akbar Dorgalaleh,
Shadi Tabibian

Jahantigh M, Naderi M, Dorgalaleh A, Tabibian S. Prevalence of Diabetes and Impaired Glucose Tolerance Test in Patients with Thalassemia Major. Zahedan J Res Med Sci. 2013;16(1):e1763. doi:

23
Sep
2007

Malocclusion in subjects with beta-thalassemia major

Fatemeh Shahsavari,
Mohammad Eslami,
MohammadHosien FarahVash

Shahsavari F, Eslami M, FarahVash M. Malocclusion in subjects with beta-thalassemia major. koomesh. 2007;8(4):e152154. doi:

Download PDF293.52 KB
Share on
Cited by
Metrics

Ordering Reprints

Articles are published under the Creative Commons license stated on each article. No permission or royalty fee is required for uses permitted by that license. CCC handles optional bulk and customized reprint orders. Any quotation covers production and delivery services only, not copyright permission. > Request Reprints from CCC